Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
classes:
Research material (131) ·
Classic Psychedelic (69) ·
Stimulant (43) ·
Opioid (29) ·
Sedative-Hypnotic (29) ·
Tryptamine (26) ·
Phenethylamine (25) ·
Botanical (23) ·
Benzodiazepine (22) ·
Anticonvulsant (19) ·
Dissociative (19) ·
Antidepressant (17) ·
Antiparkinsonian (16) ·
Antipsychotic (16) ·
Empathogen (16) ·
Analgesic (15) ·
Neuroleptic (15) ·
Cathinone (14) ·
Nootropic (13) ·
Lysergamide (12)
mechanism:
5-HT2A agonist (27) ·
GABAA positive allosteric modulator (22) ·
None (16) ·
Monoamine releasing agent (11) ·
CB1/CB2 agonist (7) ·
Potent mu-opioid receptor agonist (6) ·
Sodium channel blocker (6) ·
Dopamine/norepinephrine reuptake inhibitor (5) ·
GABAA potentiator; NMDA antagonist (5) ·
Phenothiazine D2 antagonist (5) ·
Potent 5-HT2A agonist (5) ·
5-HT1B/1D agonist (4) ·
LSD analogue; 5-HT2A agonist (4) ·
Mu-opioid receptor agonist (4) ·
Muscarinic receptor antagonist (4) ·
Prodrug of LSD; 5-HT2A agonist (4) ·
Selective norepinephrine reuptake inhibitor (4)
uses:
None (391) ·
Pain, cough, disquiet (1) ·
[[Type 2 diabetes mellitus]] (adjunct, second-line) (1) ·
[[Type 2 diabetes mellitus]] (incl. pediatric ≥10 y) · [[Obesity]] (incl. pediatric ≥12 y) · [[Cardiovascular risk reduction]] in T2DM (1) ·
[[Type 2 diabetes mellitus]] · [[Cardiovascular risk reduction]] in T2DM (1) ·
[[Type 2 diabetes mellitus]] · [[Obesity]] · [[Cardiovascular risk reduction]] in obesity without diabetes · [[MASH]] with stage 2–3 fibrosis · [[Chronic kidney disease]] in T2DM (1) ·
[[Type 2 diabetes mellitus]] · [[Obesity]] · [[Obstructive sleep apnea]] in obesity (1) ·
'"`UNIQ--vote-000003B5-QINU`"', '"`UNIQ--vote-000003B6-QINU`"', '"`UNIQ--vote-000003B7-QINU`"', '"`UNIQ--vote-000003B8-QINU`"', '"`UNIQ--vote-000003B9-QINU`"' (1) ·
'"`UNIQ--vote-00000722-QINU`"', '"`UNIQ--vote-00000723-QINU`"', '"`UNIQ--vote-00000724-QINU`"', '"`UNIQ--vote-00000725-QINU`"' (1) ·
'"`UNIQ--vote-00000BE3-QINU`"', '"`UNIQ--vote-00000BE4-QINU`"', '"`UNIQ--vote-00000BE5-QINU`"', '"`UNIQ--vote-00000BE6-QINU`"', '"`UNIQ--vote-00000BE7-QINU`"', '"`UNIQ--vote-00000BE8-QINU`"', '"`UNIQ--vote-00000BE9-QINU`"', '"`UNIQ--vote-00000BEA-QINU`"' (1) ·
'"`UNIQ--vote-00000D13-QINU`"', '"`UNIQ--vote-00000D14-QINU`"', '"`UNIQ--vote-00000D15-QINU`"', '"`UNIQ--vote-00000D16-QINU`"' (1) ·
'"`UNIQ--vote-00000F40-QINU`"', '"`UNIQ--vote-00000F41-QINU`"', '"`UNIQ--vote-00000F42-QINU`"', '"`UNIQ--vote-00000F43-QINU`"', '"`UNIQ--vote-00000F44-QINU`"' (1) ·
'"`UNIQ--vote-0000143C-QINU`"', '"`UNIQ--vote-0000143D-QINU`"', '"`UNIQ--vote-0000143E-QINU`"', '"`UNIQ--vote-0000143F-QINU`"', '"`UNIQ--vote-00001440-QINU`"', '"`UNIQ--vote-00001441-QINU`"' (1)
starting dose:
None (392) ·
0.75 mg SC weekly'"`UNIQ--ref-00000053-QINU`"' (1) ·
2.5 mg SC weekly × 4 wk (non-therapeutic ramp)'"`UNIQ--ref-000002FB-QINU`"' (1) ·
500 mg PO TID × 7-10 days (most indications); 2 g single dose for trichomoniasis; 500 mg IV q8h for severe anaerobic infection; rectal 1 g BID (1) ·
Byetta: 5 µg SC twice daily, within 60 min before morning and evening meals'"`UNIQ--ref-000000E3-QINU`"' · Bydureon BCise: 2 mg SC once weekly'"`UNIQ--ref-000000E4-QINU`"' (1) ·
HRT cyclic: 200 mg PO HS days 1-12 of each month; continuous: 100 mg PO daily; ART luteal support 100 mg vaginal TID or 90 mg gel daily (1) ·
Oral 1-2 mg daily; transdermal patch 0.025-0.05 mg/d twice weekly; transdermal gel 0.5-1 g/d; vaginal 10 mcg tablet twice weekly for GSM. Always combine with a progestogen in patients with an intact uterus. (1) ·
Oral 300-450 mg PO QID; IV 600-900 mg q8h; topical 1% solution/gel BID; vaginal 100 mg ovule × 3 days or 2% cream × 7 days (1) ·
Oral: 4-6 mL (400,000-600,000 units) suspension QID swish-and-swallow; topical: BID-QID; vaginal tablet 1 daily for 2 weeks (1) ·
Ozempic: 0.25 mg SC weekly × 4 wk'"`UNIQ--ref-00000245-QINU`"' · Wegovy: 0.25 mg SC weekly × 4 wk'"`UNIQ--ref-00000246-QINU`"' · Rybelsus: 3 mg PO daily × 30 d'"`UNIQ--ref-00000247-QINU`"' (1) ·
Topical: 1% cream BID × 2-4 weeks; vaginal: 1% or 2% cream nightly × 7 days, or 100/200/500 mg vaginal tablet single or 3-day regimens; troche: 10 mg PO five times daily × 2 weeks for thrush (1) ·
Victoza: 0.6 mg SC daily × 1 wk'"`UNIQ--ref-00000181-QINU`"' · Saxenda: 0.6 mg SC daily × 1 wk'"`UNIQ--ref-00000182-QINU`"' (1)
preparations:
None (392) ·
1% topical cream, lotion, solution; 1%, 2% vaginal cream; 100, 200, 500 mg vaginal tablets; 10 mg oral troches; combination with betamethasone (Lotrisone, Rx) (1) ·
100,000 units/mL oral suspension; 500,000 unit tablets; 100,000 units/g cream, ointment, powder; vaginal tablets (1) ·
250, 500 mg tablets; 750 mg ER; 500 mg/100 mL IV; 0.75-1% topical gel/cream; 0.75% vaginal gel; suppository (1) ·
75, 150, 300 mg capsules; 75 mg/5 mL solution; 150 mg/mL IV; 1% topical; 2% vaginal cream (1) ·
Byetta pre-filled multi-dose pen: 5 µg / 10 µg per dose'"`UNIQ--ref-000000E5-QINU`"' · Bydureon BCise single-dose autoinjector: 2 mg extended-release microsphere suspension'"`UNIQ--ref-000000E6-QINU`"' (1) ·
Oral 0.5, 1, 2 mg tablets; transdermal patches (twice-weekly and once-weekly); 0.06% gel; 1.53 mg/spray topical; vaginal ring (Estring); vaginal tablet (Vagifem/Yuvafem); vaginal cream (1) ·
Oral 100, 200 mg capsules (peanut oil; check allergy); 100 mg vaginal insert (Endometrin); 4%, 8% vaginal gel (Crinone); IM 50 mg/mL (1) ·
Pre-filled multi-dose pen (0.25 / 0.5 / 1 / 2 mg, Ozempic;'"`UNIQ--ref-00000248-QINU`"' 0.25 / 0.5 / 1 / 1.7 / 2.4 mg, Wegovy'"`UNIQ--ref-00000249-QINU`"') · Oral tablet 3 / 7 / 14 mg co-formulated with SNAC absorption enhancer (Rybelsus)'"`UNIQ--ref-0000024A-QINU`"' (1) ·
Pre-filled multi-dose pen (3 mL): Victoza 6 mg/mL (0.6 / 1.2 / 1.8 mg per day);'"`UNIQ--ref-00000183-QINU`"' Saxenda 6 mg/mL (0.6 / 1.2 / 1.8 / 2.4 / 3.0 mg per day)'"`UNIQ--ref-00000184-QINU`"' (1) ·
Pre-filled single-dose pen and vial: 2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg'"`UNIQ--ref-000002FC-QINU`"''"`UNIQ--ref-000002FD-QINU`"' (1) ·
Pre-filled single-dose pen: 0.75 / 1.5 / 3 / 4.5 mg'"`UNIQ--ref-00000054-QINU`"' (1)
fda max:
None (392) ·
1.8 mg/day SC (Victoza, T2DM)'"`UNIQ--ref-00000185-QINU`"' · 3.0 mg/day SC (Saxenda, obesity)'"`UNIQ--ref-00000186-QINU`"' (1) ·
10 µg twice daily (Byetta)'"`UNIQ--ref-000000E7-QINU`"' · 2 mg once weekly (Bydureon BCise)'"`UNIQ--ref-000000E8-QINU`"' (1) ·
15 mg/wk SC'"`UNIQ--ref-000002FE-QINU`"''"`UNIQ--ref-000002FF-QINU`"' (1) ·
2 mg/wk SC (Ozempic)'"`UNIQ--ref-0000024B-QINU`"' · 2.4 mg/wk SC (Wegovy)'"`UNIQ--ref-0000024C-QINU`"' · 14 mg PO daily (Rybelsus)'"`UNIQ--ref-0000024D-QINU`"' (1) ·
4.5 mg/wk SC'"`UNIQ--ref-00000055-QINU`"' (1) ·
4.8 g/d (IV severe infection) (1) ·
Indication-dependent; 200-400 mg/d oral typical (1) ·
Indication-specific (1) ·
Indication-specific; lowest effective dose for shortest duration is the WHI-era standard (1) ·
Topical: BID; troche: 5×/day (1) ·
~4 g/d (severe systemic infection) (1)
routes: (Click arrow to add another value)
onset:
None (392) ·
Days (1) ·
Glycemic effect within days; full weight effect over months'"`UNIQ--ref-00000301-QINU`"' (1) ·
Glycemic effect within days; near-maximal HbA1c effect by 4 weeks at any given dose'"`UNIQ--ref-00000057-QINU`"' (1) ·
Glycemic effect within days; weight effect over weeks to months'"`UNIQ--ref-00000188-QINU`"' (1) ·
Glycemic effect within days;<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> full weight effect over months'"`UNIQ--ref-00000250-QINU`"' (1) ·
Glycemic effect within hours (Byetta); weeks (Bydureon, extended-release microsphere)'"`UNIQ--ref-000000EA-QINU`"' (1) ·
Hours (2) ·
Sedation/dizziness within hours of oral dose; endometrial effects over days (1) ·
Symptom relief within days (1) ·
Vasomotor relief 2-4 weeks; bone density gains over months (1)
duration:
None (391) ·
6-8 hours (1) ·
8-12 hours (1) ·
About 20 minutes (1) ·
Hours per application (2) ·
Oral: 8-12 hours; vaginal: 24+ hours; IM: days (1) ·
Route- and formulation-dependent (1) ·
~10 hours (Byetta)'"`UNIQ--ref-000000EB-QINU`"' · ~7 days steady-state (Bydureon, after ~6–7 weeks of weekly dosing to reach steady state)'"`UNIQ--ref-000000EC-QINU`"' (1) ·
~24 h (daily dosing)'"`UNIQ--ref-00000189-QINU`"' (1) ·
~7 days (weekly dosing)'"`UNIQ--ref-00000058-QINU`"' (1) ·
~7 days (weekly dosing)'"`UNIQ--ref-00000302-QINU`"' (1) ·
~7 days (weekly SC dosing)'"`UNIQ--ref-00000251-QINU`"' · ~24 h (oral)'"`UNIQ--ref-00000252-QINU`"' (1)
halflife:
None (391) ·
6-8 hours'"`UNIQ--ref-00000BEB-QINU`"' (1) ·
9–12 minutes (intravenous) (1) ·
Not meaningfully described (minimal systemic absorption from topical use)'"`UNIQ--ref-00000F45-QINU`"' (1) ·
Not meaningfully described (not systemically absorbed)'"`UNIQ--ref-00000D17-QINU`"' (1) ·
~13 hours'"`UNIQ--ref-0000018A-QINU`"' (1) ·
~13-20 hours (oral); transdermal pharmacokinetics buffer the peaks/troughs of oral dosing'"`UNIQ--ref-000003BA-QINU`"' (1) ·
~165 hours (~1 week), among the longest of any GLP-1 RA'"`UNIQ--ref-00000253-QINU`"' (1) ·
~2.4 hours (Byetta, short, hence the BID schedule)'"`UNIQ--ref-000000ED-QINU`"' · Effective release half-life ~2 weeks (Bydureon)'"`UNIQ--ref-000000EE-QINU`"' (1) ·
~2.5-3 hours'"`UNIQ--ref-00001442-QINU`"' (1) ·
~5 days (~120 h)'"`UNIQ--ref-00000059-QINU`"' (1) ·
~5 days (~120 h)'"`UNIQ--ref-00000303-QINU`"' (1) ·
~5-20 hours (oral micronized; highly variable)'"`UNIQ--ref-00000726-QINU`"' (1)
bioavailability:
None (392) ·
Essentially zero systemic absorption from oral or topical routes — the topical-action-only profile is the basis of its safety'"`UNIQ--ref-00000D18-QINU`"' (1) ·
Oral ~5% (extensive first-pass to estrone and conjugates); transdermal bypasses first-pass, giving more physiologic estradiol:estrone ratio'"`UNIQ--ref-000003BB-QINU`"' (1) ·
Oral: very low (extensive first-pass); micronization improves uptake somewhat. Vaginal: high local effect with lower systemic levels (first-uterine-pass concentration)'"`UNIQ--ref-00000727-QINU`"' (1) ·
SC ~47%–65%'"`UNIQ--ref-0000005A-QINU`"' (1) ·
SC ~55%'"`UNIQ--ref-0000018B-QINU`"' (1) ·
SC ~65%–75%<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
SC ~80%<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
SC ~89%<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> · Oral ~0.4–1% (SNAC-enhanced)'"`UNIQ--ref-00000254-QINU`"' (1) ·
Topical: minimal systemic; troche: ~3% systemic'"`UNIQ--ref-00000F46-QINU`"' (1) ·
~80% (oral)'"`UNIQ--ref-00000BEC-QINU`"' (1) ·
~90% (oral)'"`UNIQ--ref-00001443-QINU`"' (1)
pregnancy:
None (394) ·
Avoid. Discontinue at least 1 month before planned pregnancy. Animal data show embryofetal harm.'"`UNIQ--ref-0000005B-QINU`"' (1) ·
Avoid. Discontinue before planned pregnancy.'"`UNIQ--ref-000000EF-QINU`"' (1) ·
Avoid. Discontinue before planned pregnancy.'"`UNIQ--ref-0000018C-QINU`"' (1) ·
Avoid. Discontinue ≥1 month pre-conception. May reduce oral contraceptive efficacy during titration.'"`UNIQ--ref-00000304-QINU`"' (1) ·
Contraindicated in pregnancy (use is not appropriate during gestation; class label X). Lactation considerations vary by indication.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe after the first trimester; first-trimester use weighed against indication.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe in pregnancy (no systemic absorption).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Topical and vaginal generally considered safe; widely used.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
None (391) ·
OTC (lower strengths) and [[USLegal:Prescription only|Rx-only]] (combination with betamethasone) in US (1) ·
Rx-only;'"`UNIQ--ref-0000005C-QINU`"' not a controlled substance (1) ·
Rx-only;'"`UNIQ--ref-000000F0-QINU`"' not a controlled substance (1) ·
Rx-only;'"`UNIQ--ref-0000018D-QINU`"' not a controlled substance (1) ·
Rx-only;'"`UNIQ--ref-00000256-QINU`"' not a controlled substance (1) ·
Rx-only;'"`UNIQ--ref-00000305-QINU`"' not a controlled substance (1) ·
[[USLegal:DEA Schedule I|Schedule I]] (United States) (1) ·
[[USLegal:Prescription only|Rx-only]] in US (4) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries a '''Boxed Warning''' for Clostridioides difficile colitis (one of the most C. difficile-inducing antibiotic classes)'"`UNIQ--ref-00001444-QINU`"' (1)
Showing below up to 250 results in range #1 to #250.
1
2
- 2-AI
- 2-FA
- 2-FDCK
- 2-FMA
- 25B-NBOH
- 25B-NBOMe
- 25C-NBOH
- 25C-NBOMe
- 25I-NBOH
- 25I-NBOMe
- 25N-NBOMe
- 2C-B-FLY
- 2C-C
- 2C-D
- 2C-E
- 2C-I
- 2C-P
- 2C-T-2
- 2C-T-7
3
4
- 4-AcO-DET
- 4-AcO-DiPT
- 4-AcO-DMT
- 4-AcO-MET
- 4-AcO-MiPT
- 4-FA
- 4-FMA
- 4-HO-DET
- 4-HO-DiPT
- 4-HO-DPT
- 4-HO-EPT
- 4-HO-MET
- 4-HO-MiPT
- 4-MeO-PCP
- 4F-EPH
- 4F-MPH
5
6
7
A
B
- Baeocystin
- Benzocaine
- Benztropine
- Benzydamine
- Biperiden
- Blue lotus
- Brivaracetam
- Bromantane
- Bromazepam
- Bromo-DragonFLY
- Bromocriptine
- Brompheniramine
- Bufotenin
- Bupivacaine
- Butalbital
- Butorphanol
- Butylone
C
- Cabergoline
- Caffeine
- Calea zacatechichi
- Cannabidiol
- Carbidopa/levodopa
- Carfentanil
- Carisoprodol
- Cathinone
- CBG
- CBN
- Cenobamate
- Chlordiazepoxide
- Chloroform
- Chlorpheniramine
- Chlorpromazine
- Chlorzoxazone
- Clindamycin
- Clobazam
- Clomipramine
- Clonazolam
- Clorazepate
- Clotrimazole
- Cocaine
- Codeine
- Coluracetam
- Curare
- Cyclazodone
D
- Datura
- Delta-10-THC
- Delta-8-THC
- Deschloroetizolam
- Deschloroketamine
- Desflurane
- Desipramine
- Desomorphine
- Desoxypipradrol
- DET
- Dexmedetomidine
- Dextroamphetamine
- Dextromethorphan
- Dextropropoxyphene
- Dextrorphan
- Diacetylmorphine
- Diclazepam
- Diethyl ether
- Dihydrocodeine
- Dihydroergotamine
- Dimenhydrinate
- Diphenidine
- DiPT
- Disulfiram
- DMT
- DOB
- DOC
- DOI
- DOM
- Doxylamine
- DPT
- Dronabinol
- Droperidol
- Dulaglutide
E
- Entacapone
- Ephedrine
- Ephenidine
- Ephylone
- EPT
- Ergotamine
- Escaline
- Eslicarbazepine
- Esmolol
- Estazolam
- Estradiol
- Eszopiclone
- ETH-LAD
- Ethcathinone
- Ethchlorvynol
- Ethosuximide
- Ethylmorphine
- Ethylone
- Ethylphenidate
- Eticyclidine
- Etizolam
- Etomidate
- Exenatide
F
- F-Phenibut
- Felbamate
- Fenethylline
- Fenfluramine
- Fentanyl
- Flualprazolam
- Flubromazepam
- Flubromazolam
- Flunitrazepam
- Flunitrazolam
- Fluphenazine
- Flurazepam
- Fosphenytoin
- Frovatriptan
G
H
- Halothane
- Harmaline
- Harmine
- Hawaiian Baby Woodrose
- Hexedrone
- HHC
- Hydrocodone
- Hydromorphone
- Hyoscyamine
I
J
K
L
- L-Theanine
- Lacosamide
- Lasmiditan
- Levodopa
- Levomilnacipran
- Levorphanol
- Liraglutide
- Lixisenatide
- Lofexidine
- Lormetazepam
- Loxapine
- LSA
- LSH
- LSZ
- Lurasidone